Trial · NCT01070095
The Electronic Asthma Action Plan System for Implementation in Primary Care
NCT01070095, Not applicable, Completed, Unity Health Toronto; results first posted 2019-09-13
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. The Electronic Asthma Action Plan System for Implementation in Primary Care. Trials, record NCT01070095. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01070095
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Electronic Asthma Action Plan System for Implementation in Primary Care
- NCT number
- NCT01070095
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 19 participants, actual
- Lead sponsor
- Unity Health Toronto
- Conditions
- Asthma
- Interventions
- Electronic Asthma Action Plan System
- First posted
- 2010-02-17
- Last updated
- 2019-09-13
- Results first posted
- 2019-09-13
- Limitations and caveats
- An interrupted time series design is vulnerable to temporal factors that may have affected asthma care behaviour. We report on behavioural rather than health outcomes in this study.
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician | 24 months | Number of eligible patients to whom an AAP was delivered by the physician during the intervention period (52 weeks) compared to the baseline period (52 weeks) Predictor model to include: clinic, appointment provider practitioner type, prior objective diagnosis of asthma, documented physician diagnosis of asthma, presenting complaint type, billing physician (most responsible physician/other), previous emergency department (ED) visits/hospitalizations for asthma, and current asthma control |
| Secondary | The Impact of the eAAPS on Patient-relevant Outcomes Including Hospitalisations, Emergency Room Visits, Unscheduled & Total Visits to the Doctor, Days Off Work/School, Nocturnal/Daytime Asthma Symptoms, Daytime Rescue Bronchodilator Use & Quality of Life. | Every 2 weeks for 6 months | |
| Secondary | Asthma Control Assessment | 24 months | The number of patients with asthma control determined at least once, according to symptom-based criteria (control determination required meeting one or more criteria for uncontrolled asthma or all criteria for controlled asthma). Predictor model to include: clinic, appointment provider practitioner type, prior objective diagnosis of asthma, documented physician diagnosis of asthma, presenting complaint type, billing physician (most responsible physician/other), previous emergency department (ED) visits/hospitalizations for asthma, and current asthma control |
| Secondary | Medication Escalations | 24 months | The number of patients with escalation of controller therapy Predictor model to include: clinic, appointment provider practitioner type, prior objective diagnosis of asthma, documented physician diagnosis of asthma, presenting complaint type, billing physician (most responsible physician/other), previous emergency department (ED) visits/hospitalizations for asthma, and current asthma control |
| Secondary | Appropriate Medication Changes | 24 months | Number of eligible visits in which patients who had an appropriate medication change made (i.e. escalation for poor control, and de-escalation for good control, when ascertainable) |
| Secondary | On Treatment Analysis | During the 12 month intervention period | Number of eligible patients to whom an asthma action plan (AAP) was delivered, when decision support was available (52 weeks), counting only intervention period visits in which patients completed the questionnaire before the appointment and the notification prompted clinicians to open the computerized clinical decision support system (CDSS) to take action |
| Secondary | Number of Practitioners Completing Feedback Questionnaires | 13 months | Number of practitioners completing feedback questionnaires on the system (delivered in the 1 month after end of intervention period) |
| Secondary | Ratio of Rescue to Controller Medication Prescriptions | 24 months | Ratio of rescue to controller medication prescriptions made during baseline vs intervention periods |
| Secondary | Adherence Discussions | During the 12 month intervention period | The number of patients in the intervention period in whom discussions about medication adherence took place |
| Secondary | System Uptake | During the 12 month intervention period | Actual usage of the system: number of patients for whom clinicians accessed the CDSS when actions were required |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician | 24 months | Number of patients on an asthma controller medication \[either inhaled corticosteroid (ICS), ICS/long-acting beta agonist (LABA), or leukotriene receptor antagonist (LTRA)\] for at least 1 visit in the study period, who received an AAP, and had not received/reviewed an asthma action plan in the last 6 months (a subset of the intervention population). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | The Impact of the eAAPS on Patient-relevant Outcomes Including Hospitalisations, Emergency Room Visits, Unscheduled & Total Visits to the Doctor, Days Off Work/School, Nocturnal/Daytime Asthma Symptoms, Daytime Rescue Bronchodilator Use & Quality of Life. | Every 2 weeks for 6 months | Not measured due to inadequate patient outcome measurement recruitment | ||
| SECONDARY | Asthma Control Assessment | 24 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Medication Escalations | 24 months | In the measuring therapy escalation, we eliminated visits in which patients had had a controller medication escalated within the last three months (the typical duration of a therapeutic trial) | participants | NUMBER |
| SECONDARY | Appropriate Medication Changes | 24 months | Visits | NUMBER | |
| SECONDARY | On Treatment Analysis | During the 12 month intervention period | Number of eligible patients with AAP delivery. This counts only patients for whom a prompt was presented to the clinician, so is a subset of the intervention population. We have only presented data from the Intervention Period, as this outcome pertains to the uptake of the intervention, and is not applicable to the Baseline Period. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Practitioners Completing Feedback Questionnaires | 13 months | Responding physicians. We have only presented data from the Intervention Period, as questionnaires were provided after the intervention only. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Ratio of Rescue to Controller Medication Prescriptions | 24 months | Ratio of SABAs to controllers prescribed | NUMBER | |
| SECONDARY | Adherence Discussions | During the 12 month intervention period | We have only presented data from the Intervention Period, as this was not captured in the Baseline Period. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | System Uptake | During the 12 month intervention period | Number of patients for whom clinicians accessed the CDSS when actions were required based on the information entered in the questionnaire (a subset of the total intervention group). We have only presented data from the Intervention Period, as this outcome pertains to the uptake of the intervention, and is not applicable to the Baseline Period. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician | Baseline Period | 0 | Participants | ||
| Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician | Intervention Period | 79 | Participants | ||
| Asthma Control Assessment | Baseline Period | 118 | Participants | ||
| Asthma Control Assessment | Intervention Period | 523 | Participants | ||
| Medication Escalations | Baseline Period | 106 | participants | ||
| Medication Escalations | Intervention Period | 117 | participants | ||
| Appropriate Medication Changes | Baseline Period | 113 | Visits | ||
| Appropriate Medication Changes | Intervention Period | 85 | Visits | ||
| On Treatment Analysis | Intervention Period | 81 | Participants | ||
| Number of Practitioners Completing Feedback Questionnaires | Intervention Period | 12 | Participants |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Baseline Period | STARTED | Electronic Asthma Action Plan System - Clinicians | 19 | |
| Baseline Period | STARTED | Electronic Asthma Action Plan System - Patients | 830 | |
| Baseline Period | COMPLETED | Electronic Asthma Action Plan System - Clinicians | 18 | |
| Baseline Period | COMPLETED | Electronic Asthma Action Plan System - Patients | 830 | |
| Baseline Period | NOT COMPLETED | Electronic Asthma Action Plan System - Clinicians | 1 | |
| Baseline Period | NOT COMPLETED | Electronic Asthma Action Plan System - Patients | 0 | |
| Intervention Period | STARTED | Electronic Asthma Action Plan System - Clinicians | 18 | |
| Intervention Period | STARTED | Electronic Asthma Action Plan System - Patients | 890 | |
| Intervention Period | COMPLETED | Electronic Asthma Action Plan System - Clinicians | 18 | |
| Intervention Period | COMPLETED | Electronic Asthma Action Plan System - Patients | 890 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Baseline | 0 | 0 |
| Total, all-cause mortality | Intervention | 0 | 0 |
| Total, other adverse events | Baseline | 0 | 0 |
| Total, other adverse events | Intervention | 0 | 0 |
| Total, serious adverse events | Baseline | 0 | 0 |
| Total, serious adverse events | Intervention | 0 | 0 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 30696669 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Baseline Period vs Intervention Period: Medication Escalations | Trial comparisons |
| Baseline Period vs Intervention Period: Asthma Control Assessment | Trial comparisons |
| Baseline Period vs Intervention Period: Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01070095
GET https://conductscience.org/api/trials/v1/NCT01070095/registered